Glycopeptide Microarray
Antibodies against glycoproteins or glycopeptides generally recognize the peptide backbone as a portion of the binding epitope. Therefore, CD BioGlyco has developed a highly sensitive glycopeptide microarray platform to help our customers screen antibodies against specific glycopeptide antigens. We look forward to providing you with professional and rapid solutions in the research related to glycobiology microarray.
Background
Abnormal post-translational variants of proteins may induce autoantibodies, and the change of O-linked glycosylation is one of the most significant cancer-related post-translational modifications. Short aberrant O-glycans on proteins may introduce new glycopeptide epitopes that can trigger autoantibodies. Therefore autoantibodies against cancer antigens are expected to serve as biomarkers for early cancer detection.
Currently, a new technology of glycopeptide microarray is being developed to screen for antibodies against different glycopeptide antigens and to detect glycopeptide-specific autoantibodies. Glycopeptide microarrays offer the advantages of parallelism, automation and rapidity. The parallel data detected has less error and higher precision. The emergence of this technology has played an important role in the advancement of many disciplines such as biology, genetics, clinical laboratory medicine and oncology.
Fig.1 Microarray platform for detection of MUC1 O-glycopeptide-specific antibodies. (Wandall, 2010)
Our Services
CD BioGlyco has developed glycopeptide microarray technology to help our customers map antibody epitopes and identify key residues for glycopeptide binding. Services we provide include but are not limited to:
- We pre-synthesize glycopeptides of various structures and immobilize them on microarray slides. In several circumstances, glycopeptides are modified by specific enzymes (e.g. glycosyltransferases) in solution or in situ on the microarray slide. Constructed glycopeptide microarrays are incubated with interaction partners and then detected by fluorescence or other methods for binding events.
- We use a chemoenzymatic approach to produce cancer-associated O-glycopeptide libraries in combination with a microarray platform for high-throughput detection of autoantibodies to the O-glycopeptidome. This technology allows sensitive detection of cancer-related autoantibodies to different O-glycopeptide epitopes.
Special Features
Our glycopeptide microarrays offer multiple features and provide an unparalleled high-resolution platform for precise analysis of key interactions based on various glycopeptide sequences.
- Site-specific analysis: Glycopeptide microarray assay helps identify the impact of changes in specific glycosylation sites on interactions and recognition. For example, it helps understand how glycopeptide motifs influence their interactions with immune cells to explore disease-related changes.
- Well-defined glycan types: We utilize glycopeptides synthesized chemically or enzymatically, with both glycan structures and peptide sequences known, ensuring unparalleled specificity and reproducibility.
- High-throughput analysis: Microarrays are suitable for high-throughput analysis to accelerate the discovery of novel interactions and biomarkers.
When biological samples (such as serum, cell lysates, or single cells) are applied to microarrays, glycoprotein-binding proteins (GBPs), antibodies, or other interaction partners selectively bind to corresponding glycopeptide targets. Subsequently, high-sensitivity detection is used to reveal complex mechanisms.
Workflow
Our glycopeptide microarray service is carefully designed to provide reliable, high-quality data.
- Glycopeptide synthesis and chip preparation: We use chemical or enzymatic methods to precisely synthesize glycopeptides with diverse structures. These glycopeptides are verified using mass spectrometry (MS), nuclear magnetic resonance (NMR), and other techniques. These highly purified glycopeptides are then carefully spotted onto specially treated solid surfaces using advanced printing technology in a precise, high-density array format. Our rigorous preparation process ensures the purity, integrity, and uniform presentation of each glycopeptide on the array.
- Sample preparation and microarray incubation: Our glycopeptide microarray analysis services are applicable to various biological samples, such as serum, plasma, and cell lysates. After receiving the samples, we perform appropriate processing, including purification and labeling. The samples are then incubated with the glycopeptide microarray under strictly controlled conditions to facilitate the occurrence of specific binding reactions.
- Signal detection and data acquisition: After incubation, non-specific binding molecules are removed through rigorous washing steps, followed by scanning of the microarray using a high-resolution, high-sensitivity microarray scanner. Advanced detection technology ensures the capture of even weak binding events, providing relevant quantitative data.
- Data analysis and interpretation: Raw intensity data undergoes a comprehensive bioinformatics processing workflow. Our specialized analysis transforms complex data into clear, actionable insights, highlighting key biological discoveries and potential biomarkers.

Advantages
- Wide range of applications: Our services are compatible with a variety of biological samples, including body fluids, cell lysates, plasma, and more from different sources. This broad applicability makes it useful in many research fields.
- Minimal sample requirements: Analysis requires only a small amount of precious biological samples, making it an ideal choice for testing rare samples.
- High sensitivity and quantitative data: Our services are suitable for detecting subtle differences in binding affinity and low-abundance interactions, providing reliable quantitative insights for specific glycan type identification.
Applications
- Biomarker discovery: Glycopeptide microarray analysis is suitable for identifying novel disease-specific glycan type biomarkers for early detection, prognosis assessment, and monitoring of cancers, autoimmune diseases, and more.
- Vaccine development: Glycopeptide microarray analysis is suitable for analyzing vaccine binding characteristics, providing useful information for vaccine development.
- Basic glycobiology research: Glycopeptide microarray analysis is suitable for elucidating the binding preferences of GBPs, thereby helping to reveal how these proteins recognize and bind to targets on the cell surface or in the extracellular matrix.
Publication Data
Technology: Glycopeptide microarray
Journal: Journal of the American Chemical Society
IF: 14.4
Published: 2023
Results: Macrophage galactose-type lectin (MGL) is a popular target for cancer vaccines. In this study, the researchers used solid-phase peptide synthesis to make a candidate vaccine that targets MGL on antigen-presenting cells, which has a high-affinity sugar cluster based on a tetraphenylethylene scaffold. The study found that immunization with this newly designed vaccine construct carrying GalNAc glycan clusters induced higher titers of anti-Tn-MUC1 antibodies. The antibodies obtained could bind to tumor-associated glycan structures on MUC1 and MUC1-positive breast cancer cells. Researchers assessed antibody selectivity using a glycopeptide microarray binding assay, which showed that the glycan clusters do not affect the recognition pattern of the antibodies. This study provides support for the design and development of vaccines targeting MGL.
Fig. 1 Antibody binding specificity to the mucin core and glycopeptides produced by vaccines 15 and 16. (Gabba, et al., 2023)
Frequently Asked Questions
With a large and well-equipped platform, CD BioGlyco provides high-quality glycopeptide microarray services to clients around the world, and we have comprehensive capabilities to meet your specific needs on glycopeptide microarray analysis. If you need our services, please contact us for more details and technical support.
Associated Services

- GPI Anchor Pathway-based Glyco-engineered Cell Construction Service
- Glycolipids (GSL) Pathway-based Glyco-engineered Cell Construction Service
- N-linked Glycan Pathway-based Glyco-engineered Cell Construction Service
- O-GalNAc Pathway-based Glyco-engineered Cell Construction Service
- O-Fuc Pathway-based Glyco-engineered Cell Construction Service
- O-Man Pathway-based Glyco-engineered Cell Construction Service
- C-Man Pathway-based Glyco-engineered Cell Construction Service
- O-Glc Pathway-based Glyco-engineered Cell Construction Service
Reference
- Gabba, A.; et al. MUC1 glycopeptide vaccine modified with a GalNAc glycocluster targets the macrophage galactose C-type lectin on dendritic cells to elicit an improved humoral response. Journal of the American Chemical Society. 2023, 145(24): 13027-13037. (Open Access)
Quick Links
Resources
- Glyco™ Synthesis Platform
- Custom Glycoprotein Synthesis
- Custom Glycoside Synthesis
- Custom Glycosyl Donor Synthesis
- Custom Thioglycoside Synthesis
- Custom Phosphatidylinositol Synthesis
- Custom Cyclodextrin Synthesis
- Custom Rhamnolipid Synthesis
- Custom Sphingolipid Synthesis
- Custom Building Block Synthesis
- Carbohydrate Manufacturing
- Synthesis Process Development and Optimization
- Custom Carbohydrate Synthesis
- Custom Glycolipid Synthesis
- Custom Glycopeptide Synthesis
- Custom Glycoconjugate Synthesis
- Custom Sugar-Nucleotide Synthesis
- Nucleoside & Nucleotide Synthesis Service
- Custom Oligonucleotide Synthesis Service
- Polynucleotide Synthesis Service
- Nucleoside & Nucleotide Modification Service
- Oligonucleotide Modification Service
- Nucleoside-based Production Service
- Nucleotide-based Production Service
- OPME-based NDP-sugar Synthesis Service
- OPME-based NMP-sugar Synthesis Service
- Glycomics Platform
- Glycoproteomics Platform
- N-Glycoproteomics of PDX Models
- Nanotechnologies for the Detection of Glycopeptides
- Glycoprotein Enrichment
- Glycoprotein Quantification
- Glyco-biomarker Detection Service
- Glyco-biomarker AFP Detection Service
- Glyco-biomarker CA19-9 Detection Service
- Glyco-biomarker CA125 Detection Service
- Glyco-biomarker CA15–3 Detection Service
- Glyco-biomarker CEA Detection Service
- Glyco-biomarker PSA Detection Service
- Glyco-biomarker Immunoglobulin G (IgG) Detection Service
- Glyco-biomarker Haptoglobin (Hp) Detection Service
- Glyco-biomarker α1-Antitrypsin (A1AT) Detection Service
- Glyco-biomarker α1-Acid Glycoprotein (AGP) Detection Service
- Glyco-biomarker Ceruloplasmin (CP) Detection Service
- Glyco-biomarker Fetuin A Detection Service
- Site Occupation
- Glycoprotein Structure Analysis
- Glycosylation Site-specific Antibody-Drug Conjugate (ADC) Development Platform
- Carbohydrate-based Glycomedicine Development Platform
- By Sources of Carbohydrate
- By Types of Carbohydrate
- Monosaccharides-based Glycomedicine Development
- Disaccharides-based Glycomedicine Development
- Trisaccharides-based Glycomedicine Development
- Oligosaccharides-based Glycomedicine Development
- Polysaccharides-based Glycomedicine Development
- Glycosides-based Glycomedicine Development
- Glycopeptide-based Glycomedicine Development
- Glycomimetic-based Glycomedicine Development
- By Applications of-based Glycomedicines
- Carbohydrate-based Anticoagulant Glycomedicine Development
- Carbohydrate-based Cardiovascular Glycomedicine Development
- Carbohydrate-based Antitumor Glycomedicine Development
- Carbohydrate-based Antidiabetic Glycomedicine Development
- Carbohydrate-based Antibacterial Glycomedicine Development
- Carbohydrate-based Antiviral Glycomedicines Development
- Carbohydrate-based Antiparasiti Glycomedicine Development
- By Discovery Strategies
- Glycoengineering-based Glycomedicine Development
- Production of Food Ingredients
- Multi-omics Platform for Cancer Glucose Metabolism (MOPCGM)
- Cancer Cell Glycolytic Analysis
- Cancer Cell TCA Cycle Analysis
- Cancer Cell PPP Analysis
- Gene-level Regulation Analysis of Cancer Glucose Metabolism
- Interplay Between Glucose Metabolism Reprogramming and Tumorigenesis & Progression
- Interplay Between Glucose Metabolism Reprogramming and Proliferative Signaling
- Interplay Between Glucose Metabolism Reprogramming and Growth Suppressor
- Interplay Between Glucose Metabolism Reprogramming and Cancer Cell Death
- Interplay Between Glucose Metabolism Reprogramming and Replicative Immortality
- Interplay Between Glucose Metabolism Reprogramming and Angiogenesis
- Interplay Between Glucose Metabolism Reprogramming and Invasion & Metastasis
- Interplay Between Glucose Metabolism Reprogramming and Immune Escape
- Interplay Between Glucose Metabolism Reprogramming and Genomic Instability
- Interplay Between Glucose Metabolism Reprogramming and Tumor-associated Inflammation
- Glucose Metabolism-Microenvironment Crosstalk Analysis in Cancer
- Cancer Glucose Metabolism In Vivo Analysis
- Applications of Studing Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism Small Molecule Inhibitor
- Discovery of Cancer Glucose Metabolism Therapeutic Monoclonal Antibodies
- Development of Gene Therapy Targeting Cancer Glucose Metabolism
- Discovery of Cancer Glucose Metabolism CAR-T Therapy Targeting
- Discovery of Cancer Glucose Metabolism Combination Therapy Strategy
- Discovery of Cancer Glucose Metabolism Precision Therapeutic Strategies
- Glycoengineering Platform
- Therapeutic Nucleic Acid Development Platform
- Therapeutic Oligonucleotide Synthesis Service
- siRNA Synthesis
- miRNA Synthesis
- ASO Synthesis
- Aptamer Synthesis
- PMO Synthesis
- sgRNA Synthesis
- Circular RNA Synthesis
- PNA Synthesis
- Lipid-based GalNac-RNA Delivery Service
- CpG Oligonucleotide Synthesis
- Click-based GalNac-RNA Delivery Service
- AntimiR Synthesis
- GalNAc-siRNA Delivery Service
- tRNA Synthesis
- GalNAc-ASO Delivery Service
- saRNA Synthesis
- Reporter Gene mRNA Synthesis
- Gene Editing mRNA Synthesis
- Gene Replacement mRNA Synthesis
- Cre Recombinase mRNA Synthesis
- hEPO mRNA Synthesis
- OVA mRNA Synthesis
- Therapeutic Oligonucleotide Modification Service
- Therapeutic Oligonucleotide Delivery Development Service
- Targeted Ligand and Linker Synthesis
- Monoantennary GalNac-RNA Delivery
- Biantennary GalNac-RNA Delivery
- Triantennary GalNac-RNA Delivery
- Tetra-antennary GalNac-RNA Delivery
- Solution Phase-based GalNac-RNA Delivery
- Solid Phase-based GalNac-RNA Delivery
- mRNA Poly(A) Tail Length Analysis
- GalNAc-siRNA Delivery
- GalNAc-ASO Delivery
- GalNAc-miRNA Delivery
- GalNAc-Aptamer Delivery
- GalNAc-AntimiR Delivery
- GalNAc-mRNA Delivery
- GalNAc-PNA Delivery
- Peptide-Therapeutic Oligonucleotide Delivery
- LNP-Therapeutic Oligonucleotide Delivery
- PEG-Therapeutic Oligonucleotide Delivery
- Biological Evaluation Service for Therapeutic Oligonucleotide
- mRNA-based Vaccine Development Service
- mRNA Sequence Design&Optimization Service
- mRNA Integrity Analysis ServicemRNA Integrity Analysis Service
- mRNA Biodistribution Analysis Service
- DNA Template Preparation Service
- mRNA Purity Analysis Service
- T Cell Cytokine Secretion Analysis Service
- mRNA Modification Service
- mRNA Length Analysis Service
- mRNA Purification Service
- Neutralizing Antibody Assay Service
- mRNA-LNP Formulation and Encapsulation Service
- mRNA Structural Characterization
- mRNA Structural Characterization Service
- mRNA Bioanalysis Service
- mRNA Residual DNA Template Analysis Service
- mRNA Residual Double-Stranded RNA (dsRNA) Analysis Service
- mRNA Size Analysis Service
- mRNA Polydispersity Analysis Service
- mRNA Zeta Potential Analysis Service
- mRNA Lipid Composition Analysis Service
- Oligonucleotide Drug Process and Formulation Development Service
- RNA Drug Process and Formulation Development
- Therapeutic Oligonucleotide Synthesis Service
- Glycobiology Microarray Platform
- Glyco™ Vaccine Development Platform
- Carbohydrate-based Vaccine Development
- Polysaccharide Vaccine Development
- Tumor-Associated Carbohydrate Vaccine Development
- Glycoconjugate Vaccine Development
- Natural Carbohydrate-based Vaccine Development
- Semi-synthetic Carbohydrate-based Vaccine Development
- Fully Synthetic Carbohydrate-based Vaccine Development
- Carbohydrate-based Antibacterial Vaccine Development
- Carbohydrate-based Antifungal Vaccine Development
- Carbohydrate-based Antiparasitic Vaccine Development
- Carbohydrate-based Antiviral Vaccine Development
- Carbohydrate-based Anticancer Vaccine Development
- Carbohydrate-based Antihelmintic Vaccine Development
- Monovalent Carbohydrate-based Vaccine Development
- Polyvalent Carbohydrate-based Vaccine Development
- Carrier Protein Design Service
- Carbohydrate Conjugation Service for Vaccine Development
- Carbohydrate-based Adjuvant Development
- Lipopolysaccharide-based Adjuvant Development
- Bacterial Outer Membrane Vesicles (OMVs)-based Adjuvant Development
- Trehalose Glycolipid-based Adjuvant Development
- Galactosylceramide-based Adjuvant Development
- Peptidoglycan-based Adjuvant Development
- Chitin/Chitosan-based Adjuvant Development
- Inulin-based Adjuvant Development
- Mannans-based Adjuvant Development
- Alginate-based Adjuvant Development
- Saponin-based Adjuvant Development
- α-Glucan-based Adjuvant Development
- Lentinan-based Adjuvant Development
- β-Glucans-based Adjuvant Development
- Deltin-based Adjuvant Development
- Muramyldipeptide-based Adjuvant Development
- Cord Factor-based Adjuvant Development
- Zwitterionic Polysaccharide-based Adjuvant Development
- Novel Plant Polysaccharides-based Adjuvant Development
- Glycoprotein-based Vaccine Development
- Glycopeptide-based Vaccine Development
- Carbohydrate-based Vaccine Development
- Glycogenomics Platform
- Glycogene Editing Service
- Glycogene Delivery Service
- Glycogene Expression Profiling
- Cancer Glycogene Discovery Service
- Glycogene Discovery Service in Cervical Cancer
- Glycogene Discovery Service in Leukemia
- Glycogene Discovery Service in Bladder Cancer
- Glycogene Discovery Service in Colorectal Adenocarcinoma
- Glycogene Discovery Service in Liver Cancer
- Glycogene Discovery Service in Lymphoma
- Glycogene Discovery Service in Breast Cancer
- Glycogene Discovery Service in Prostate Cancer
- Glycogene Discovery Service in Pancreatic Cancer
- Glycogene Discovery Service in Lung Cancer
- Glycogene Discovery Service in Thyroid Cancer
- Glycogene Discovery Service in Ovarian Cancer
- Glycan Display Platform
- Traditional Glycan Display Array
- Natural Oligosaccharide Library Construction Service
- Chemical Synthesis-based Oligosaccharide Library Construction Service
- Enzymatic Synthesis-based Oligosaccharide Library Construction Service
- Modular Synthesis-based Oligosaccharide Library Construction Service
- Oligosaccharide Library Immobilization Service
- Cell-based Glycan Display Array
- Neoglycolipid (NGL) Display Array
- Liquid Glycan Display Array (LiGA)
- Glycophage Display
- N-linked Glycoprotein-based Glycophage Display System Construction Service
- O-linked Glycoprotein-based Glycophage Display System Construction Service
- Glycophage Display-based Glycosylase Genetic Analysis Service
- Glycophag Display-based Glycoarray Service
- Glycophage Display-based Antibody Development Service
- Glycophage Display-based Epitope Mapping Service
- Glycophage Display-based Biomarker Development Service
- De Novo Glycan Display
- Cell-Surface Glycan Editing
- Examining the Effects of Altering Blood Group Antigens on Erythrocyte Cell Surfaces
- Preventing Cellular Rejection During Transplantation
- Modulating Chemical Composition and Physical Parameters of Glycocalyx
- Tailoring Cell Membranes with Biologically Active Glycans
- Targeting Glycosaminoglycan-mediated Growth Factor Signaling to Influence Stem Cell Specification
- Long-term De Novo Glycan Display for Directing Stem Cell Fate
- Traditional Glycan Display Array
- GlycoNano™ Platform
- Glyconanoparticle Development Service
- Techniques for Glyconanoparticle Development
- Carbohydrate-based Nanoparticle Production
- Gold Glyconanoparticle Production
- Silver Glyconanoparticle
- Magnetic Glyconanoparticle
- Quantum Dot (QD) Glyconanoparticle
- Glyconanoparticle Characterization
- PEG Glyconanoparticle
- Carbon-based Glyconanoparticle
- Fluorescent Glyconanoparticle
- Silica Glyconanoparticle
- Liposome Glyconanoparticle
- Glycol Nanohydrogel Development
- Glycol Nanorod
- Glycol Nanotube
- Glycol Nanocrystal/Nanosheet/Nanosphere/Nanofiber
- Glyconanoparticle Preclinical Study
- Glyconanoparticle Formulation
- Glyconanotechnology-based Biosensor Development
- GlycoNano™ Bioink Production for 3D Printing
- Glyconanoparticle Development Service
- Glyco™ Synthesis Platform





